Needham Maintains Buy on Conmed, Raises Price Target to $140
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Mike Matson maintains a Buy rating on Conmed (NYSE:CNMD) and raises the price target from $139 to $140.
July 27, 2023 | 9:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson maintains a Buy rating on Conmed and raises the price target from $139 to $140.
The news of Needham maintaining a Buy rating and raising the price target for Conmed is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100